Slingshot members are tracking this event:
Novartis drug Afinitor receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET)
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|NVS||Community voting in process|
Slingshot Insights Explained
Jun 02, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Advanced Gastrointestinal, Lung Neuroendocrine Tumors, Net